COVID-19-Related Thrombosis in Japan: Final Report of a Questionnaire-Based Survey in 2020
-
- Horiuchi Hisanori
- The Japanese Society of Thrombosis and Hemostasis The Japan Atherosclerosis Society Department of Molecular and Cellular Biology, Institute of Development, Aging and Cancer, Tohoku University
-
- Morishita Eriko
- The Japanese Society of Thrombosis and Hemostasis The Japan Atherosclerosis Society The Research Study Team for Intractable Disease (Blood Coagulation Abnormalities) supported by the Ministry of Health, Labour and Welfare of Japan Department of Clinical Laboratory Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Health Sciences, Kanazawa University
-
- Urano Tetsumei
- The Japanese Society of Thrombosis and Hemostasis Department of Medical Physiology, Hamamatsu University School of Medicine
-
- Yokoyama Kenji
- The Japanese Society of Thrombosis and Hemostasis The Research Study Team for Intractable Disease (Blood Coagulation Abnormalities) supported by the Ministry of Health, Labour and Welfare of Japan Department of Hematology/Oncology, Tokai University Hachioji Hospital
この論文をさがす
抄録
<p>A questionnaire on COVID-19-related thrombosis in patients hospitalized before Aug 31, 2020, was sent to 399 hospitals throughout Japan. Responses were received from 111 (27.8%) with information on 6,202 COVID-19 patients. Of these, 333 and 56 required ventilation or extracorporeal membrane oxygenation (ECMO), respectively, and 212 died (3.4%). D-dimer levels were measured in 75.0% of the patients, revealing that 9.2% and 7.6% exhibited D-dimer increases of 3-8-fold and ≥8-fold the reference value, respectively. Thrombotic events occurred in 108 patients (1.86% of the 5,807 patients with available data) including symptomatic cerebral infarction in 24, myocardial infarction in 7, deep vein thrombosis in 41, pulmonary thromboembolism in 30, and other thrombotic events in 22. Some patients developed multiple thrombotic events. Thrombosis occurred in 32 patients with mild or moderate COVID-19 severity (0.59% of those with data available) and in 52 patients on ventilation or ECMO (13.5% of severe patients for whom data were available). Thrombosis occurred in 67 patients during worsening clinical condition and in 26 during recovery. Anticoagulant therapy was provided to 893 patients (14.6% of the 6,119 patients with available data), the main reasons being provided as elevated D-dimer levels and worsening clinical condition.</p>
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ
-
Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ 28 (4), 406-416, 2021-04-01
一般社団法人 日本動脈硬化学会